ACCRUFER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(6 years from now) | |
| US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(10 years from now) | |
Accrufer is owned by Shield Tx.
Accrufer contains Ferric Maltol.
Accrufer has a total of 3 drug patents out of which 0 drug patents have expired.
Accrufer was authorised for market use on 25 July, 2019.
Accrufer is available in capsule;oral dosage forms.
Accrufer can be used as method of treating iron deficiency.
Drug patent challenges can be filed against Accrufer from 26 July, 2023.
The generics of Accrufer are possible to be released after 23 October, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 26 July, 2023
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE;ORAL
More Information on Dosage
ACCRUFER family patents
